PUBLISHER: Allied Market Research | PRODUCT CODE: 1538917
PUBLISHER: Allied Market Research | PRODUCT CODE: 1538917
The global dermal filler market was valued at $5,184.8 million in 2021, and is projected to reach $14,418.4 million by 2031, registering a CAGR of 10.8% from 2022 to 2031. Dermal filler is defined as an aesthetic procedure, which is injected beneath the surface of the skin to add fullness & volume, smooth lines & soften creases, and increase the facial contours. It is widely used for facial aesthetic treatment. The different types of dermal filler are hyaluronic acid, calcium hydroxylapatite, polylactic acid, and polymethyl-methacrylate microspheres. It is used to enhance or fill the shallow areas on the face. In addition, this procedure is mostly used among population to reduce wrinkle under eyes.
The growth of the global dermal filler market is majorly driven by an alarming increase in demand for minimally invasive procedure; rise in government initiative for the advancement of dermal filler procedure; surge in the number of approvals for dermal filler' products; and a rise in adoption of hyaluronic acid. According to the journal of Dermatology & Mohs Surgery Institute, it was analyzed that dermal filler is one of the leading minimally invasive skin procedure, globally. For instance, in 2021, Deloitte, one of the leading professional services companies, reported that around 9.53% of hyaluronic acid is consumed in China. Thus, the increase in prevalence of hyaluronic acid boosts the demand for dermal filler procedure.
Moreover, in 2021, the U.S. Food and drug Administration (FDA) announced the approval of RHA Redensity Dermal Filler, which is used for the treatment of moderate to severe dynamic perioral rhytids (lip lines) in the adults above the age of 22. Furthermore, in 2021, Revance Therapeutics, Inc., a biotechnology company, presented data on the effectiveness and safety of the RHA collection of dermal filler. It is one of the latest advances in hyaluronic acid filler technology, which is used for the treatment of moderate-to-severe nasolabial folds in darker skin color. The increase in advancements in dermal filler technology aims to obtain long-lasting, and effective results. Thus, advancements in technology for advanced dermal filler products in emerging nations are expected to propel the growth of the market.
The increase in government support for aesthetic procedure and surge in demand for aesthetic procedure are the major factors that drive the global dermal filler market. For instance, in February 2022, the GOV.UK announced to introduce a licensing regime for non-surgical cosmetic procedures such as dermal filler and Botox. This step aims to protect the public against botch fillers and botox. In addition, increase in the number of anti-aging treatment significantly contributes toward the market growth. Rise in demand for aesthetic looks among young population acts a key driving force for the expansion of the global market.
However, the high cost associated with dermal filler procedure is anticipated to hinder the market growth. Increase in prevalence of early skin aging, surge the need for hyaluronic acid and drive the growth of the market. This has further encouraged many key players to enter emerging markets, thus offering a lucrative growth opportunity in the dermal filler market.
The dermal filler market is segmented into type, gender, service provider, and region. By type, the market is categorized into hyaluronic acid (HA), calcium hydroxylapatite (CaHA), poly-L-lactic acid, and others. The others segment is further divided into polymethyl-methacrylate microspheres (PMMA) and fat face. By gender, it is bifurcated into male and female. By service provider, the market is classified into specialty & dermatology clinics, hospitals, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global dermal filler market are include AbbVie Laboratories, Bioxis pharmaceutical, Cutera Inc., Elan aesthetics Inc., Galderma SA, Merz Pharma GmbH & Co. KGaA, Revance Therapeutics, Sinclair Pharma, Teoxane Laboratories, and Vital Esthetique Laboratories.
Additional benefits you will get with this purchase are:
◦ 13 to 39
◦ 40 to 54
◦ 55 to 69